nirogacestat

an antineoplastic agent

Also Known As:

2-(5,7-difluoro-1,2,3,4-tetrahydronaphthalen-3-ylamino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide; PF 03084014; PF 3084014; PF-03084014; PF-3084014; PF03084014; PF3084014

Networked: 41 relevant articles (11 outcomes, 14 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Zhang, Cathy C: 5 articles (10/2018 - 09/2012)
2.	Zhang, Qin: 4 articles (03/2015 - 09/2012)
3.	Olson, Peter: 3 articles (10/2018 - 03/2015)
4.	Cesari, Rossano: 3 articles (03/2018 - 01/2015)
5.	Huang, Bo: 3 articles (03/2018 - 01/2015)
6.	Zheng, Xianxian: 3 articles (03/2015 - 09/2012)
7.	Yan, Zhengming: 3 articles (06/2014 - 09/2012)
8.	Randolph, Sophia: 3 articles (01/2014 - 06/2010)
9.	Du, Zhongbo: 2 articles (01/2021 - 07/2018)
10.	Li, Luo: 2 articles (01/2021 - 07/2018)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2020 - "It is an exciting time for Notch research with over 70 cancer clinical trials registered and the first-ever Phase III trial of a Notch GSI, nirogacestat, currently at the recruitment stage." 06/01/2010 - "Additional mechanism-of-action studies showed inhibition of tumor cell proliferation and induction of apoptosis in HPB-ALL tumors, suggesting that the antitumor activity of PF-03084014 may be mediated by its direct effects on tumor cell growth or survival. " 01/01/2020 - "We found that PF-3084014 treatment led to a significantly smaller tumor burden and higher survival ratio in patient-derived xenograft mice as compared to the vehicle. " 01/01/2020 - "Finally, we used patient-derived xenograft mouse model to demonstrate the tumor inhibitory effects of Notch-inhibitor, PF-3084014. " 01/01/2017 - "We further tested the PF-03084014 in PDX models and confirmed the inhibition tumor growth effect. "
2.	Aggressive Fibromatosis (Desmoid) 01/01/2023 - "Nirogacestat effective in desmoid tumours." 03/01/2018 - "PF-03084014 was effective in treating desmoid tumors, with an objective response rate of 71.4% (95% CI 29.0-96.3%) in this small cohort of patients. " 03/09/2023 - "We conducted a phase 3, international, double-blind, randomized, placebo-controlled trial of nirogacestat in adults with progressing desmoid tumors according to the Response Evaluation Criteria in Solid Tumors, version 1.1. " 01/01/2023 - "Nirogacestat and its potential impact on desmoid tumor." 05/10/2017 - "Conclusion PF-03084014 was well tolerated and demonstrated promising clinical benefit in patients with refractory, progressive desmoid tumors who receive long-term treatment."
3.	Triple Negative Breast Neoplasms 03/01/2013 - "In this report, we aimed to evaluate the antitumor efficacy of PF-03084014 in combination with docetaxel in triple-negative breast cancer models. " 01/10/2017 - "In this phase Ib, open-label, multicenter study (NCT01876251), we evaluated PF-03084014, a selective gamma-secretase inhibitor in patients with advanced triple-negative breast cancer. " 01/10/2017 - "Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer."
4.	Hepatocellular Carcinoma (Hepatoma) 01/01/2017 - "In addition, a low dose of PF-03084014 induced hepatocellular carcinoma sphere differentiation, resulting in chemosensitization. " 01/01/2017 - "In this study, we investigated the antitumor and antimetastasis efficacy of the novel Notch inhibitor (γ-secretase inhibitor) PF-03084014 in hepatocellular carcinoma. " 01/01/2017 - "Collectively, PF-03084014 revealed antitumor and antimetastatic effects in hepatocellular carcinoma, providing evidence for the potential use of gamma-secretase inhibitors as a therapeutic option for the treatment of hepatocellular carcinoma. " 01/01/2017 - "PF-03084014 reduced the hepatocellular carcinoma sphere-derived orthotopic tumor and blocked the hepatocellular carcinoma tumor liver to lung metastasis. " 01/01/2017 - "Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1-Stat3."
5.	Multiple Myeloma 01/01/2021 - "Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. "

Related Drugs and Biologics

1.	Amyloid Precursor Protein Secretases (beta-Secretase)
2.	nirogacestat
3.	Docetaxel (Taxotere)
4.	Irinotecan (Camptosar)
5.	dostarlimab
6.	Messenger RNA (mRNA)
7.	Glucocorticoids
8.	Gemcitabine
9.	Jagged-1 Protein
10.	enzalutamide

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Therapeutics
3.	Castration
4.	Oral Administration